EP Patent

EP3342779A1 — Inhibitors of transglutaminases

Assigned to Zedira GmbH · Expires 2018-07-04 · 8y expired

What this patent protects

The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use for the prophylaxis and treatment of diseas…

USPTO Abstract

The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use for the prophylaxis and treatment of diseases associated with transglutaminases.

Drugs covered by this patent

Patent Metadata

Patent number
EP3342779A1
Jurisdiction
EP
Classification
—
Expires
2018-07-04
Drug substance claim
No
Drug product claim
No
Assignee
Zedira GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.